Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial

Abstract

Abstract is not available.

    Similar works

    Full text

    thumbnail-image

    Available Versions